؉ as a substrate and is inhibited by nicotinamide analogues. sPARP-1 produces pADPr of similar length and structure to that of PARP-1. However, contrary to PARP-1, sPARP-1 does not require DNA strand breaks for its activation, although it is stimulated following genotoxic treatments.
Poly(ADP-ribosyl)ation is a covalent post-translational modification of nuclear proteins that is induced by DNA strand breaks and represents an immediate cellular response to DNA lesions caused by environmental insults (1) . Extensive but transient pADPr synthesis is triggered within the nucleus after treatment of mammalian cells with genotoxic agents such as ionizing radiation or alkylation (2, 3) . Poly(ADP-ribosyl)ation also takes place during many processes such as DNA repair (4 -7), replication (8, 9) , and transcription (10, 11) , regulation of cell cycle progression (12, 13) , and cell differentiation (1, 14) .
Poly(ADP-ribose) polymerase 1 (PARP-1 1 ; EC 2.4.2.30), the only well characterized enzyme in animal cells that catalyzes pADPr synthesis, comprises three functional domains: a DNAbinding domain, an automodification domain, and a catalytic domain (15) . The amino-terminal DNA-binding domain (apparent molecular mass 46 kDa) contains two zinc fingers, responsible for the recognition and binding to both single and double DNA strand breaks, as well as a bipartite nuclear localization signal (16) . The 55-kDa carboxyl-terminal domain that bears the NAD ϩ -binding site and the catalytic activity represents the most highly conserved part of the enzyme (3, 17, 18) . The enzymatic activity of the COOH-terminal domain is greatly enhanced upon the binding of PARP-1 to DNA strand breaks (15, 19 -21) . The central 16-kDa automodification domain is rich in glutamic acid residues, which are sites for covalent binding of pADPr (22) . This domain contains a BRCT domain, a putative site of interactions with other proteins (23, 24) .
To better define the biological functions of PARP-1 and poly-(ADP-ribosyl)ation, PARP-1 (Ϫ/Ϫ) mice have been independently generated by three groups (25) (26) (27) . The primary phenotype in these animals is genomic instability following DNA damage (26, 28) . Although a slightly reduced proliferation rate is observed in derived PARP-1 (Ϫ/Ϫ) cells, no effect on cell cycle profile or on cell differentiation has been reported. Moreover, the homozygous mutant mice develop normally and are fertile (29) . These observations are hard to reconcile with previous studies showing that poly(ADP-ribosyl)ation is involved in many important processes related to DNA metabolism. However, recent studies have shown that PARP-1 (Ϫ/Ϫ) cells retain the ability to synthesize pADPr following treatment with genotoxic agents, suggesting the presence of an as yet unidentified enzyme with this activity (30) . This idea is supported by the discovery of two structurally different and functionally active PARP proteins in plants (31, 32) as well as a human PARP-like protein, called tankyrase (33) . Three recent papers describe the cloning of new PARP family members cDNAs from mouse and human cells (PARP-2 and PARP-3) (34 -36) .
In this paper, we show that a poly(ADP-ribose) polymerase activity is present in immortalized PARP-1 (Ϫ/Ϫ) embryonic mouse fibroblasts (25) , and report the cloning of a cDNA that encodes a protein responsible for pADPr synthesis. The enzyme, designated sPARP-1 (for short poly(ADP-ribose) polymerase 1), is identical to the catalytic domain of PARP-1 and shares most of the well documented features of the carboxylterminal part of PARP-1. The determination of the chromosomal localization of sPARP-1 gene leads us to conclude that both sPARP-1 and PARP-1 are products of the PARP-1 gene. sPARP-1 is present in wild type and PARP-1 (Ϫ/Ϫ) cells and is localized in the nucleus. Although the poly(ADP-ribose) polymerase activity of sPARP-1 is DNA strand break-independent, it is strongly stimulated by genotoxic treatments such as alkylation and UV irradiation, suggesting the involvement of PARP-1 and sPARP-1 in different types of DNA damage-inducible response pathways.
EXPERIMENTAL PROCEDURES
Reagents-The enzymes poly(ADP-ribose) polymerase-1 and poly-(ADP-ribose) glycohydrolase were purified as described previously (37, 38) . The PARP-1 inhibitors 3-aminobenzamide (3-AB), 1,5-dihydroxyquinolinediol, and 3-methoxybenzamide were obtained from Sigma-Aldrich Canada (Oakville, Ontario), as well as the alkylating agent, N-methyl-NЈ-nitro-N-nitrosoguanidine (MNNG), and DNase I-activated DNA. All reagents were of analytical grade.
Cell Culture-The mouse fibroblast L (PARP-1 (ϩ/ϩ)), the PARP-1 (Ϫ/Ϫ) mouse embryo fibroblast A1, and the A1 mother cell line F20 (PARP-1 (ϩ/ϩ)) (25) were grown at 37°C in a humidified 5% CO 2 atmosphere. The medium (Life Technologies, Inc.) was modified Eagle's medium containing 0.2% bicarbonate for L cells, and Dulbecco's modified Eagle's medium low glucose supplemented with 1% L-glutamine and 0.2% bicarbonate for A1 and F20 cells. Penicillin (100 g/ml), streptomycin (100 g/ml), and 10% fetal bovine serum were added to both media. A1 cells were always maintained in presence of 600 g/ml neomycin (Life Technologies, Inc.) as a selection agent (25) .
Treatment of Cells-Cells grown to 80% confluence were treated at 37°C for various times with either 100 M MNNG in serum-free medium or with a germicidal lamp (G. W. Gates & Co. Inc., New York) at a dose of 30 J/m 2 as verified with an ultraviolet meter (Ultra-Violet Products Inc., Upland, CA). To study the inhibition of pADPr synthesis, cells were preincubated with 2 mM 1,5-dihydroxyquinolinediol for 5 min at 37°C.
PADPr and NAD ϩ Quantification-PADPr and NAD ϩ were affinity purified on a dihydroxyboronyl-Bio-Rex 70 matrix as described earlier (39) except that the elutions were performed with water at 37°C. The amount of synthesized pADPr was estimated by immunodot blot (40) , while the analysis and measurements of NAD ϩ were performed using an enzyme cycling assay (39) .
Cloning of sPARP-1 cDNA-Total RNA was extracted from PARP-1 (Ϫ/Ϫ) cells according to the method of Chomczynski and Sacchi (41) . Three g of RNA were reverse-transcribed at 42°C using oligo(dT) 16 primers (Amersham Pharmacia Biotech) and Moloney murine leukemia virus reverse transcriptase (Promega) according to the instructions of the manufacturer. For PCR amplification, primers were chosen based on the cDNA sequences present in the catalytic domain of PARP-1 that were most conserved among species (5Ј-primer: 5Ј-CTTCTGGAGGAC-GACAAGGA-3Ј; 3Ј-primer: 5Ј-CCACAGGGATGTCTTAAAAT-3Ј). Restriction sites EcoRI and HindIII were added to the 5Ј-and 3Ј-primers, respectively. Five l of the reverse transcription reaction mixture was directly added to 95 l of PCR reaction mixture containing thermopol buffer, 200 M of each dNTP, 100 mM MgSO 4 , 15 pmol of each 3Ј-and 5Ј-primer, and 0.8 units of Vent DNA polymerase for 30 cycles at 94°C for 1 min, 60°C for 1 min. and 72°C for 2 min. We obtained thus a partial cDNA of sPARP-1, referred to as sPARPcat, which was cloned into EcoRI-HindIII restriction sites of pBlueScript SK Ϫ (Stratagene). The 5Ј end of the sPARP-1 cDNA was amplified using the Marathon cDNA amplification kit from CLONTECH. First-strand cDNA was obtained by reverse transcription of 1 g of total RNA extracted from A1 cells catalyzed by 100 units of Moloney murine leukemia virus reverse transcriptase and using oligo(dT) 16 primer (Amersham Pharmacia Biotech) in a final reaction volume of 15 l. To synthesize the secondstrand, 10 l of the reverse transcription reaction mixture was incubated with 40 units of Escherichia coli DNA polymerase I, 1.5 units of RNase H, and 15 units of E. coli DNA ligase in a final volume of 80 l according to the CLONTECH protocol. After 1.5 h of incubation at 16°C, 10 units of T4 DNA polymerase were added to the reaction mixture and further incubated at 16°C for 45 min to create blunt ends on the double-stranded cDNA. The Marathon cDNA adaptor was ligated to the 5Ј and 3Ј extremities of the phenol-purified doublestranded cDNA, using 1 unit of T4 DNA ligase to catalyze this reaction at 16°C overnight. 5Ј-Rapid amplification of cDNA ends was performed with an adaptor primer supplied with the kit (AP2; CLONTECH) and the 3Ј gene-specific primer described above (30 cycles at 94°C for 30 s, 60°C for 30 s, and 68°C for 3 min). The correct PCR product was identified by hybridization using 32 P-labeled sPARPcat as a probe, purified from agarose gel (Geneclean TM Spin, Bio-101) and reamplified using AP2 and a 3Ј nested gene-specific primer containing SacI restriction site (5Ј-CATCCCCACCAGCTCCTGCACTG-3Ј) (5 cycles at 94°C for 30 s, 72°C for 3 min, 5 cycles at 94°C for 30 s, 70°C for 3 min; 25 cycles at 94°C for 20 s, 68°C for 3 min). The PCR product (5Ј-sPARP) was then introduced in XbaI and SacI restriction sites of pBluescript SK Ϫ . The total cDNA for sPARP-1 was sequenced according to the Sanger method (42) .
Radiation gene Hybrid Mapping-The 5Ј-untranslated region of the sPARP-1 gene was PCR amplified using the following pair of primers: 5Ј-GGTGAAGATGAGTAAGAAGATGG-3Ј (forward) and 5Ј-GGTGCT-GTCAAGGAAGGAG-3Ј (reverse). These primers yield a 235-bp product from mouse genomic DNA but no amplification from hamster genomic DNA. The PCR screening of the mouse T31 panel, which contained DNA from 100 radiation hybrid clones plus two control DNAs (donor 129aa and recipient A23), was accomplished at Research Genetics, Inc., Huntsville, AL. To map the sPARP-1 gene, the data vector, obtained by scoring the radiation hybrid clones for a presence or absence of the 235-bp product specific for the sPARP-1 gene, was submitted to the web server of MIT Whitehead Institute.
Genomic Southern Blot Analysis-Mouse genomic DNA was isolated from fibroblast cells and subjected to Southern blotting according to the standard procedure (43) . Ten micrograms of the genomic DNA was digested with each of EcoRI, HindIII, BamHI, or PstI restriction endonucleases, fractionated on a 0.7% agarose gel and alkaline-transferred to a Hybond N ϩ membrane (Amersham Pharmacia Biotech). The blot was hybridized with 32 P-labeled 235-bp PCR product, generated by the primers used for radiation hybrid mapping.
Activity-Western Blot Analysis-Sample preparation was carried out essentially as described earlier (44) except that protease inhibitor mixture tablets (Complete, Mini; Roche Molecular Bichemicals, Ontario, Canada) were used as antiproteases. The poly(ADP-ribosyl)ation activity was visualized as described previously (45) . Briefly, samples were resolved on a 10% SDS-polyacrylamide gel, the gel was then soaked at 37°C in Tris glycine running buffer containing 0.7 M 2-mercaptoethanol and the proteins were transferred onto a Hybond C nitrocellulose membrane (Amersham Pharmacia Biotech). After refolding of proteins in renaturation buffer (50 mM Tris/HCl, pH 8.0, 100 mM NaCl, 1 mM dithiothreitol, 0.3% Tween), the enzymatic reaction was started by incubating the membrane in the same buffer supplemented with 2 g/ml DNase I-activated DNA, 2 mM Mg 2ϩ , 20 M Zn 2ϩ
, and 100 M NAD ϩ . Noncovalently bound pADPr was removed by four washes with SDS wash buffer (50 mM Tris/HCl, pH 8.0, 100 mM NaCl, 1 mM dithiothreitol, 2% SDS). Finally, covalently automodified proteins were detected by using a 1:500 diluted monoclonal antibody 10H, directed against the pADPr (46) and visualized with 1:5000 diluted secondary peroxidase-coupled anti-mouse antibody (Jackson ImmunoReasearch) and enhanced chemiluminiscence reagent (Renaissance ECL-Plus, DuPont). The chemical and enzymatic stripping of the activity-Western blots were performed as described earlier (44) .
Development of Antibody and Western Blotting of sPARP-1-A peptide (MPSKEDAVEHFMKLY) chosen from the predicted amino acid sequence of sPARP-1 was synthesized on a four-branch Multiple Antigenic Peptide resin (47, 48) using a 433A Applied Biosystems Peptide Synthesizer with Fast-MOC chemistry and injected into a rabbit to raise the polyclonal antipeptide antibody (LR98 -196) directed against sPARP-1. The antiserum was affinity purified on Affi-Gel 10 resin (Bio-Rad) coupled with the same peptide. For Western blot analysis of sPARP-1, nuclear proteins from PARP-1 (ϩ/ϩ) and PARP-1 (Ϫ/Ϫ) cells were resolved on an 8% SDS-polyacrylamide gel, electrotransferred onto a nitrocellulose membrane (Amersham Pharmacia Biotech), and blocked in phosphate-buffered saline containing 5% skimmed milk and 0.1% Tween. Blots were incubated overnight with affinity purified LR98 -196 diluted 1:100 followed by goat anti-rabbit antibody coupled to peroxidase (Jackson ImmunoReasearch) diluted 1:2500 in blocking sPARP-1 Is a PARP with DNA Strand Break-independent Activitysolution. Immunocomplexes were detected by ECL (Renaissance ECLPlus, DuPont).
Cell Fractionation-Cells grown to 80% confluence in 100-mm dishes were incubated for 7 min with 500 l of buffer A (300 mM sucrose, 10 mM Tris-HCl, pH 7.8, 3 mM MgCl 2 , 1 mM Na 2 EDTA, 2 mM ␤-mercaptoethanol, Complete TM Mini antiprotease mixture (Roche Molecular Biochemicals)) supplemented with 0.03% Nonidet P-40. After homogenization with a glass-Teflon homogenizer (20 strokes), the suspension was centrifuged for 5 min at 800 ϫ g. The cytoplasmic supernatant was removed and the pelleted nuclei were washed three times in 500 l of buffer A. The nuclear proteins were solubilized in SDS-polyacrylamide gel electrophoresis reducing loading buffer (49), sonicated, and kept at Ϫ80°C for further analyses. All the steps were performed at 4°C.
Purification of sPARP-1-PARP-1 (Ϫ/Ϫ) cells were grown in basal Dulbecco's modified Eagle's medium without methionine and supplemented with 400 Ci of [
35 S]methionine (1,000 Ci/mmol; NEN TM Life Science Products, Inc.). The nuclear fraction prepared as described above was resuspended in column loading buffer (50 mM Tris-HCl, pH 7.4; 1M NaCl, 10 mM 2-mercaptoethanol, one Complete TM Mini protease inhibitor mixture tablet (Roche Molecular Biochemicals) per 10 ml of buffer) and sonicated on ice. The protein lysate was loaded on an Econo-Column containing 400 l of equilibrated 3-AB-Affi-Gel matrix prepared as described elsewhere (50) . The column was washed with 10 ml of equilibration buffer followed by elution with a 10 mM solution of 3-methoxybenzamide. Fractions of 200 l were recovered and 30 l of each fraction was analyzed by autoradiography after a 10% SDS-polyacrylamide gel electrophoresis.
PADPr Blot Analysis-PADPr was analyzed by electrophoresis at 400 V on a 20% polyacrylamide gel essentially as described elsewhere (51) . PADPr was transferred onto a Hybond N ϩ membrane (Amersham Pharmacia Biotech) and immunodetected as described previously (52) .
Immunofluorescence Microscopy-PARP-1 (Ϫ/Ϫ) cells, grown to confluence on coverslips, were treated with 200 M MNNG for 20 min, briefly washed with ice-cold phosphate-buffered saline, and fixed in acetone/methanol (0.3/0.7, v/v) at Ϫ20°C for 10 min. After saturation in phosphate-buffered saline containing 10% non-fat milk and 0.1% Tween, cells were incubated in the same buffer with the polyclonal antibody LP96 -10 diluted 1:250 (52) , and subsequently with a 1:50 diluted secondary Texas Red-coupled anti-rabbit antibody (Jackson ImmunoResearch). Slides were analyzed by indirect fluorescence microscopy. For the immunoanalysis using the polyclonal anti-peptide antibody LR98-196, the procedure was essentially the same, except that PARP-1 (Ϫ/Ϫ) cells were not treated with alkylating agent and the secondary antibody was fluorescein isothiocyanate-conjugated anti-rabbit antibody.
DNA Breaks Measurement-PARP-1 (Ϫ/Ϫ) cells grown to 80% confluence in 6-well plates, were treated for different time intervals with 100 M MNNG as described above. The genomic DNA was extracted and prepared as described previously (53) . The 3Ј end of DNA breaks was radiolabeled by a nucleotide exchange reaction catalyzed by the T4 DNA polymerase (Amersham Pharmacia Biotech) in the presence of [ 32 P]dCTP (NEN TM Life Science Products, Inc.) and quantified according to the method of Legault et al. (53) .
RESULTS

PADPr Synthesis in PARP-1(Ϫ/Ϫ) Cells after Genotoxic
Treatment-Treatment of cells with alkylating agents such as MNNG usually leads to pADPr synthesis. In contrast, other genotoxic agents, like UVC for instance, do not significantly induce the synthesis of pADPr. PARP-1 is the only well characterized enzyme responsible for the synthesis of pADPr following DNA damage. To determine whether PARP-1 is solely responsible for pADPr synthesis, we have studied this activity in PARP-1 (Ϫ/Ϫ) cells. Wild type and mutant cells were treated with 100 M MNNG or UVC irradiated with a dose of 30 J/m 2 for different periods of time up to 60 min. After purification by affinity chromatography, the amount of pADPr at each time point was measured by an immunodot blot assay as described earlier (39, 40) . Table I (Fig.  1A) . To detect the pADPr synthesized during the reaction, we used a monoclonal antibody directed against pADPr (46) . These activity-Western blots were conducted in the presence or absence of NAD ϩ . Purified bovine PARP-1 was loaded in the left lane as a positive control. As expected, in the presence of NAD ϩ , the major band in PARP-1 (ϩ/ϩ; L) cells appears at 113 kDa as a result of the catalytic activity of PARP-1. However, it is accompanied by a second band corresponding to a protein with a molecular mass of approximately 60 kDa that possesses poly(ADP-ribose) polymerase activity (Fig. 1A, lanes 2, 4, and  6 ). Only this latter protein is present in PARP-1 (Ϫ/Ϫ) cells (Fig. 1A, lanes 1, 3, and 5) . The signal intensity of 113-and 60-kDa bands depends on the amount of loaded cells and therefore manifests that these two signals represent specific enzymatic activities. In the absence of NAD ϩ , no enzymatic activities were detected, clearly demonstrating that, as for PARP-1, NAD ϩ is a substrate for the 60-kDa enzyme. Moreover, when these activity-Western blots were performed in the presence of 1 mM 3-AB, a PARP-1 inhibitor, pADPr synthesis was inhibited in purified bovine PARP-1 (a positive control for inhibition), 
(Ϫ/Ϫ) and PARP-1 (ϩ/ϩ) cells following genotoxic treatments
Cells were treated with either MNNG (100 M) or UVC (30 J/m 2 ). The amount of purified pADPr as well as purified NAD ϩ was determined as described under "Experimental Procedures." The data shown are the mean Ϯ S.E. of at least three independent experiments. All these results are expressed in function of the amount of DNA. The amounts of synthesized pADPr are net values obtained after subtraction of the basal level for the corresponding cell line. and in the samples isolated from PARP-1 (ϩ/ϩ; L) and PARP-1 (Ϫ/Ϫ) cells (data not shown). Thus, the 60-kDa enzyme, like PARP-1 appears to bind 3-AB leading to its inhibition.
To determine the subcellular localization of the novel poly-(ADP-ribose) polymerase activity, PARP-1 (Ϫ/Ϫ) cells were fractionated into nuclei and cytoplasm and activity-Western blots were performed on these two fractions. The 60-kDa enzyme was found predominantly in the nuclear fraction (Fig.  1B) . The intensity of the band at approximately 60 kDa increases proportionally to the amount of loaded proteins, indicating that the signal is due to a specific catalytic activity. The faint signal in the cytoplasmic fraction may come from a minor nuclear contamination. When similar activity-Western blots were performed without NAD ϩ , no band was observed (data not shown). The subcellular localization of this activity was also studied in situ using indirect immunofluorescence. PARP-1 (Ϫ/Ϫ) cells were grown to confluence on coverslips, treated with 200 M MNNG for 20 min, and stained with a polyclonal antibody directed against pADPr and subsequently with a secondary, Texas Red-conjugated antibody. No signal was observed in untreated cells (Fig. 1C, panel 4) , but following MNNG treatment, pADPr was detected in the cell nuclei (Fig.  1C, panels 1 and 3) . Thus, in agreement with the nuclear localization of the 60-kDa protein (Fig. 1B) , these immunocytochemistry studies indicate that the poly(ADP-ribose) polymerase activity is present exclusively in the nucleus of PARP-1 (Ϫ/Ϫ) cells.
Based on our findings showing a nuclear localization and an inhibition of its enzymatic activity by 3-AB, we carried out the purification of the 60-kDa protein as described under "Experimental Procedures" (Fig. 1D) . Since the elution was made with a solution of 3-methoxybenzamide, another nicotinamide analogue and inhibitor of poly(ADP-ribosyl)ation, the purified protein was not active as confirmed by activity-Western blot (data not shown).
sPARP-1 cDNA and Chromosomal Localization of sPARP-1 Gene-By using total RNA purified from PARP-1 (Ϫ/Ϫ) fibroblast cells and primers chosen among the most highly conserved sequences of PARP-1, a partial cDNA was isolated and then subcloned into pBlueScript SK Ϫ . The rapid amplification of cDNA ends technique was employed to isolate the full-length cDNA. The 1732-bp complete cDNA was sequenced and found to be identical to the catalytic domain of the mouse PARP-1. The complete sequence is available in GenBank under the accession number AF126717. An open reading frame in the DNA sequence lies between nucleotides 252 and 1730. The deduced amino acid sequence of this open reading frame corresponds to the catalytic domain of the mouse PARP-1 and contains all the amino acids required for the binding of NAD ϩ and for the poly(ADP-ribose) polymerase activity. Therefore we called this new isolated protein sPARP-1 for short poly(ADPribose) polymerase 1. The nucleotide sequence from 1 to 251 corresponds to the 5Ј-untranslated region of the mRNA of sPARP-1 and is different from the 5Ј-untranslated region sequence of the mouse PARP-1. At position 141 in the 5Ј-untranslated region, upstream of the predicted translation start point, an in-frame stop codon was found indicating that the cloned cDNA contains the entire open reading frame.
The similarity between the cDNA sequences of sPARP-1 and the catalytic domain of PARP-1 suggested that only one gene encoded for these two proteins. Therefore we carried out the chromosomal mapping of the sPARP-1 gene by radiation hybrid analysis. A comprehensive radiation hybrid map of the mouse genome is presently available (55) . The mouse T31 panel was screened in duplicate using PCR primers amplifying the 235-bp product from the 5Ј-untranslated region sequence of sPARP-1 to identify the clones containing the sPARP-1 locus. The linkage analysis of the raw data mapped our marker on the chromosome 1 of the Whitehead Institute (MIT) framework map between the markers D1Mit459 and D1Mit509, 101 centimor- 1 and 2) , 300,000 (lanes 3 and 4) , and 200,000 (lanes 5 and 6) cells were resolved on a 10% polyacrylamide gel and electroblotted onto a nitrocellulose membrane. After renaturation of proteins and poly(ADP-ribose) synthesis in the presence of NAD ϩ , membranes were probed with a monoclonal antibody 10H directed against pADPr. A protein with an apparent molecular mass of 60 kDa which synthesize pADPr is present in both PARP-1 (Ϫ/Ϫ) (lanes 1, 3, and 5) and PARP-1 (ϩ/ϩ) (lanes 2, 4, and 6) cells. Purified bovine PARP-1 (0.1 units) was run as a positive control (first lane). B, detection of poly(ADP-ribose) polymerase activity in fractionated PARP-1 (Ϫ/Ϫ) cells by activity-Western blot. The nuclear (left panel) and cytoplasmic (right panel) fractions prepared from 200,000, 150,000, 75,000, and 50,000 PARP-1 (Ϫ/Ϫ) cells (lanes 1, 2, 3 , and 4, respectively) were analyzed for the presence of poly(ADP-ribose) polymerase activity by activity-Western blot. The 60-kDa protein able to form poly(ADP-ribose) is found in the nuclear fraction. C, in situ immunodetection of poly(ADP-ribose) synthesized in PARP-1 (Ϫ/Ϫ) cells by indirect immunofluorescence microscopy. PARP-1 (Ϫ/Ϫ) cells grown under standard conditions were mock-treated (panels 2 and 4) or treated (panels 1 and 3) with 200 M MNNG for 20 min. Poly(ADP-ribose) was detected by a polyclonal rabbit antibody followed by Texas Red-conjugated anti-rabbit antibody. The slides were examined either by phase-contrast (lanes 1 and 2) or fluorescence microscopy ( panels 3 and 4) . D, purification of sPARP-1 from PARP-1 (Ϫ/Ϫ) cells. PARP-1 (Ϫ/Ϫ) cells grown with [ 35 S]Met were fractionated into cytoplasmic and nuclear fractions. The nuclear fraction was briefly sonicated in the chromatography loading buffer at 4°C and loaded onto a 3-AB-coupled Affi-Gel matrix column. The elution of sPARP-1 was done with 10 mM 3-methoxybenzamide. Loading, washing, and elution fractions (lanes 1-4) were subjected to SDS-polyacrylamide gel electrophoresis, and then the gel was exposed for autoradiography.
sPARP-1 Is a PARP with DNA Strand Break-independent Activity
gans (LODϾ3.0). This locus corresponds to the cytogenetic band 1H5 where is previously localized the mouse PARP-1 gene and thereby indicates that sPARP-1 mRNA originates from this gene.
Concurrently to the RH mapping, we performed Southern blot analysis of digested mouse genomic DNA as described under "Experimental Procedures." This analysis revealed the presence of one or at most two bands consistent with a single copy gene as well (data not shown).
Identification of sPARP-1 as the Enzyme Responsible for the Poly(ADP-ribose) Polymerase Activity Found in PARP-1 (Ϫ/Ϫ)
Cells-Previous studies by others have shown that the 40-kDa carboxyl-terminal end of PARP-1 contains the amino acids essential for its catalytic activity and is sufficient to support poly(ADP-ribose) polymerase activity (19) . Since sPARP-1 virtually represented the catalytic domain of PARP-1, it was expected to have poly(ADP-ribose) polymerase activity and, as confirmed by in vitro expression of sPARP-1 cDNA (data not shown), sPARP-1 was competent to catalyze pADPr formation.
To determine whether sPARP-1 is identical to the 60-kDa protein responsible for poly(ADP-ribosyl)ation seen in PARP-1 (Ϫ/Ϫ) and PARP-1 (ϩ/ϩ) cells (Fig. 1, A and B) , we developed a polyclonal antibody (LR98-196) directed against a peptide from the deduced amino acid sequence of the catalytic domain of sPARP-1. It is noteworthy that the peptide chosen to develop the LR98-196 antibody is absent in all of the recently described PARP homologues. Western blot analysis using this antibody and activity-Western blotting were performed in parallel, on the same membrane, with nuclear protein extracts from PARP-1 (ϩ/ϩ) and PARP-1 (Ϫ/Ϫ) cells (Fig. 2A) . sPARP-1 is detected by the LR98-196 antibody in both PARP-1 (ϩ/ϩ) and PARP-1 (Ϫ/Ϫ) nuclear extracts and accurately comigrates with the protein bearing poly(ADP-ribose) polymerase activity. Furthermore, the staining of methanol-fixed PARP-1 (Ϫ/Ϫ) cells with anti-sPARP-1 antibody revealed a stain pattern consistent with nuclear accumulation of sPARP-1 (Fig. 2B) . The immunodetection of sPARP-1 in the nucleus either by Western blotting (Fig. 2A) or by immunofluorescence (Fig. 2B) demonstrated that the subcellular distribution of sPARP-1 coincided with the poly(ADP-ribosyl)ation activity found in PARP-1 (Ϫ/Ϫ) cells (Fig. 1, B and C) . Taken together, our results demonstrate that sPARP-1 is expressed in both PARP-1 (ϩ/ϩ) and PARP-1 (Ϫ/Ϫ) cells and is in part responsible for the pADPr formation.
The Activation of sPARP-1 Is DNA Break-independent-As shown in Table I , sPARP-1 is activated following treatment with DNA damaging agents, suggesting that it could be activated by DNA strand breaks. To test this hypothesis, activityWestern blots were performed with whole PARP-1 (Ϫ/Ϫ) cell extract in the presence or absence of DNase I-treated calf thymus DNA (Fig. 3, A and B, respectively) . Equal amounts of purified bovine PARP-1 were used as a positive control (Fig. 3,  A and B, left lane) . As expected, the activity of purified PARP-1 increased in the presence of DNA treated with DNase I. In contrast, the activity of sPARP-1 does not appear to be stimulated by activated DNA since the intensity of the signal obtained with or without DNase I-damaged DNA is similar (Fig.  3, A and B) . However, the signal intensity depends on the amount of cells loaded showing that the activity which this signal represents is specific. This result strongly suggests that, unlike PARP-1, sPARP-1 activation is independent of DNA strand breaks.
To confirm this finding, PARP-1 (Ϫ/Ϫ) cells were treated with 100 M MNNG during a time course. Kinetics of DNA strand break formation and pADPr synthesis were determined and compared (Fig. 3C) . Within the first 10 min of the MNNG treatment, the number of DNA strand breaks increases four times without considerable synthesis of pADPr. However, while the increase in DNA strand breaks is only 1.19-fold (from 10 to 20 min of the kinetic), pADPr synthesis rises sharply to 5.85 pmol/mg of DNA, a more than 3-fold increase. These kinetics thus indicate that the pADPr synthesis in PARP-1 (Ϫ/Ϫ) cells does not correlate with the DNA strand break formation. Taken together, these results demonstrate that DNA strand breaks do not directly activate sPARP-1.
Analysis of pADPr Synthesized by sPARP-1-PADPr from 1 ϫ 10 8 cells treated with 200 M MNNG for 20 min was purified by affinity chromatography. After separation on a 20% polyacrylamide gel, the pADPr was transferred onto a positively charged nitrocellulose filter and immunodetected by a polyclonal antibody (Fig. 4, lane 1) . Five pmol of pADPr synthesized in vitro by purified PARP-1 was run as a positive control (Fig. 4, lane 2) . The electrophoresis was performed until the bromphenol blue dye ran out of the gel. Under these conditions, xylene cyanol dye migrates with the 20-mer pADPr (51) . The lengths of pADPr synthesized by sPARP-1 in PARP-1 (Ϫ/Ϫ) cells and in vitro generated pADPr by purified PARP-1 appear to be similar (Fig. 4) . Moreover, purified poly(ADPribose) glycohydrolase was able to hydrolyze pADPr synthesized by sPARP-1 suggesting structural similarities between the pADPr synthesized by PARP-1 and by sPARP-1 (data not shown). Our observations are consistent with a study of Shieh et al. (30) which reports that pADPr synthesized by PARP-1 (Ϫ/Ϫ) cells is indistinguishable from that of wild type cells by sPARP-1 Is a PARP with DNA Strand Break-independent Activityseveral criteria. We therefore conclude that the characteristics of pADPr synthesized by either of these poly(ADP-ribose) polymerases cannot confer them a different cellular function.
DISCUSSION
This work was initiated to elucidate the presence of poly-(ADP-ribose) polymerase activity that we found in PARP-1 (Ϫ/Ϫ) cells (Table I) . We cloned from those cells a cDNA encoding a protein that has an amino acid sequence identical to the catalytic domain of the mouse PARP-1. Therefore we named this protein sPARP-1. sPARP-1 is expressed in both PARP-1 (Ϫ/Ϫ) and PARP-1 (ϩ/ϩ) cells. sPARP-1 gene belongs to the same locus as PARP-1 gene does. Therefore we suggest that PARP-1 and sPARP-1 are encoded by the same gene. Multiple mRNAs encoded by a single gene have already been reported for other mouse genes (56) . There are three possible ways for a gene to provide different mRNAs: an alternative splicing of the pre-mRNA, an alternative transcription starting point, or both. PARP-1 (Ϫ/Ϫ) mice have been generated by inserting an inframe neomycin cassette containing a stop codon and a synthetic polyadenylation site between exon 2 and intron 2. Thus the full-length PARP-1 mRNA is not present in PARP-1 (Ϫ/Ϫ) cells as shown previously (25) . In this case, an alternative splicing of PARP-1 pre-mRNA cannot occur in those cells. Therefore, we suggest that sPARP-1 mRNA is a product of an alternative transcription initiation site within the PARP-1 gene. The misdetection of sPARP-1 mRNA in the earlier study by Wang et al. (25) may result from the specificity of the labeled probe used for Northern blot analysis or from its low transcription level.
Very recently, three novel PARP-1 homologues have been reported in different organisms (34 -36) thus forming a family of poly(ADP-ribose) polymerases. The common feature of these enzymes is a cluster of amino acids called "PARP signature," which is implicated in the binding and enzymatic processing of NAD ϩ , their substrate, to form pADPr. The poly(ADP-ribose) polymerases known so far can conditionally be divided into two groups in respect to their mode of catalytic activation: dependent and independent of DNA strand breaks. The classical members PARP-1 and ZAP, isolated from mammals and maize, respectively, and some of their truncated homologues, like NAP/APP (31, 32) from plants and mammalian PARP-2 (36), are known to require DNA strand breaks for their activation. On the other hand, although the mechanism of enzymatic activation of other family members as tankyrase (33) , vault PARP (57), and reported herein sPARP-1 is still ambiguous, it does not appear to be mediated by DNA breaks. While sPARP-1 activation is DNA strand break-independent, we show that it is induced following DNA damage. One interpretation of our findings may involve the stimulation of sPARP-1 as a part of a biochemical and/or signaling pathway that operates in cells in response to genotoxic insults. In this model, sPARP-1 enzymatic activation may result from protein-protein interactions between up-stream acting components of the pathway. Recently, PARP-1 enzyme activity was reported to be up-regulated in ␥-irradiated murine keratinocytes through the binding of E1A adenovirus protein to the transcriptional coactivator sPARP-1 Is a PARP with DNA Strand Break-independent Activityp300/CBP, although this activation did not involve an increase in PARP-1 gene expression (58) . Alternatively, sPARP-1 induction following genotoxic treatments may be regulated by posttranslational modification of this protein, like phosphorylation for instance. Indeed, PARP-1 activity was previously shown to be modulated by phosphorylation during Xenopus laevis oocyte maturation and the presence of multiple sites for phosphorylation in PARP-1 has been suggested (59) . Whatever the mode of activation of sPARP-1 is, it would apparently define the specificity of sPARP-1 action and function in cells, since sPARP-1 actually represents the catalytic domain of PARP-1 and both enzymes synthesize identical pADPr.
The emergence of a family of PARP enzymes expands the field of poly(ADP-ribosyl)ation and adds to the understanding of the pleiotropic effects of PARP inhibitors observed in previous studies. Presently it is difficult to determine which poly-(ADP-ribose) polymerase is responsible for the residual poly-(ADP-ribosyl)ation observed in PARP-1 (Ϫ/Ϫ) cells. While it is now demonstrated that two additional poly(ADP-ribose) polymerases, stimulated following genotoxic treatment, are present in mammalian cells, sPARP-1 (this paper) and PARP-2 (36), their particular contribution to the overall poly(ADP-ribosyl)ation process is still unclear. Amé et al. (36) demonstrated that DNase I-treated DNA enhances PARP-2 catalytic activity 15 times. In contrast, we showed that sPARP-1 activity is not directly stimulated by DNA strand breaks. In Fig. 3B , we present the kinetics of pADPr synthesis and generation of DNA strand breaks in PARP (Ϫ/Ϫ) cells treated with 100 M MNNG. The results clearly show that pADPr is synthesized in two steps. The first peak of pADPr synthesis is concomitant with the generation of DNA strand breaks and could therefore be attributed to PARP-2. In contrast, the second peak of pADPr synthesis appears later, independently of the generation of DNA lesions, and could be assigned to sPARP-1. We therefore suggest that sPARP-1 may be implicated in the later stages of the cellular response to DNA damage.
The physiological role of these novel poly(ADP-ribose) polymerases remains to be elucidated. One can suggest that these enzymes could serve as a backup for PARP-1, since PARP-1 (Ϫ/Ϫ) mice developed normally although poly(ADP-ribosyl)ation has been implicated in vital processes such as replication, transcription, and differentiation. However, the hypersensitivity of PARP-1 (Ϫ/Ϫ) mice to genotoxic treatments suggests that these new enzymes cannot entirely compensate for PARP-1 functions. Despite the fact that the mode of activation of DNAindependent PARP-1 homologues like sPARP-1, tankyrase and V-PARP remain to be clarified, their presence and activity in cells reinforce the importance of poly(ADP-ribosyl)ation. Generation of mice lacking a single or more members of the PARP family will be a critical step toward the elucidation of the particular function for these enzymes as well as the role of poly(ADP-ribosyl)ation.
